CLEC-2 Prevents Accumulation and Retention of Inflammatory Macrophages During Murine Peritonitis

Joshua Bourne, Noni Beristain Covarrubias, Malou Zuidscherwoude, Joana Campos, Ying Di, Evelyn Garlick, Martina Colicchia, Lauren Terry, Steven Thomas, Alexander Brill, Jagadeesh Bayry, Steve Watson, Julie Rayes

Research output: Contribution to journalArticlepeer-review

78 Downloads (Pure)

Abstract

Platelets play a key role in the development, progression and resolution of the inflammatory response during sterile inflammation and infection, although the mechanism is not well understood. Here we show that platelet CLEC-2 reduces tissue inflammation by regulating inflammatory macrophage activation and trafficking from the inflamed tissues. The immune regulatory function of CLEC-2 depends on the expression of its ligand, podoplanin, upregulated on inflammatory macrophages and is independent of platelet activation and secretion. Mechanistically, platelet CLEC-2 and also recombinant CLEC-2-Fc accelerates actin rearrangement and macrophage migration by increasing the expression of podoplanin and CD44, and their interaction with the ERM proteins. During ongoing inflammation, induced by lipopolysaccharide, treatment with rCLEC-2-Fc induces the rapid emigration of peritoneal inflammatory macrophages to mesenteric lymph nodes, thus reducing the accumulation of inflammatory macrophages in the inflamed peritoneum. This is associated with a significant decrease in pro-inflammatory cytokine, TNF-α and an increase in levels of immunosuppressive, IL-10 in the peritoneum. Increased podoplanin expression and actin remodelling favour macrophage migration towards CCL21, a soluble ligand for podoplanin and chemoattractant secreted by lymph node lymphatic endothelial cells. Macrophage efflux to draining lymph nodes induces T cell priming. In conclusion, we show that platelet CLEC-2 reduces the inflammatory phenotype of macrophages and their accumulation, leading to diminished tissue inflammation. These immunomodulatory functions of CLEC-2 are a novel strategy to reduce tissue inflammation and could be therapeutically exploited through rCLEC-2-Fc, to limit the progression to chronic inflammation.
Original languageEnglish
Article number693974
JournalFrontiers in immunology
Volume12
DOIs
Publication statusPublished - 7 Jun 2021

Fingerprint

Dive into the research topics of 'CLEC-2 Prevents Accumulation and Retention of Inflammatory Macrophages During Murine Peritonitis'. Together they form a unique fingerprint.

Cite this